Arrowhead Pharmaceuticals Q2 2023 Earnings Report
Key Takeaways
Arrowhead Pharmaceuticals reported a net income attributable to Arrowhead Pharmaceuticals, Inc. of $48.675 million, or $0.45 per diluted share, for the fiscal second quarter ended March 31, 2023. The company earned milestone payments from Takeda and GSK.
Reported interim results from an ongoing Phase 1/2 clinical study of ARO-RAGE for inflammatory pulmonary diseases.
Announced a planned R&D Day on June 1, 2023, including presentations on cardiometabolic, pulmonary, and central nervous system (CNS) pipeline programs.
Earned a $40 million milestone payment from Takeda after the first patient was dosed in the Phase 3 REDWOOD clinical study of fazirsiran for the treatment of alpha-1 antitrypsin deficiency associated liver disease (AATD-LD).
Earned a $30 million milestone payment from GSK following the start of GSK’s Phase 2b trial of GSK4532990, formerly called ARO-HSD, for the treatment of patients with non-alcoholic steatohepatitis (NASH).
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals
Forward Guidance
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. They leverage RNA interference to induce rapid, deep, and durable knockdown of target genes.